Duvelisib

Generic Name
Duvelisib
Brand Names
Copiktra
Drug Type
Small Molecule
Chemical Formula
C22H17ClN6O
CAS Number
1201438-56-3
Unique Ingredient Identifier
610V23S0JI
Background

Duvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma can produce a broad adaptative and innate immune cell inhibitory activity. All the work around duvelisib showed that this agent is a potent inhibitor of bo...

Indication

Duvelisib is indicated for the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in adult patients who have trialed at least two prior therapies.

Associated Conditions
Refractory Small Lymphocytic Lymphoma, Relapsed Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia (CLL), Relapsed Small Lymphocytic Lymphoma
Associated Therapies
-

A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype

Phase 3
Not yet recruiting
Conditions
Interventions
First Posted Date
2024-07-26
Last Posted Date
2024-11-20
Lead Sponsor
SecuraBio
Target Recruit Count
124
Registration Number
NCT06522737

A Study of Duvelisib Combined With SG001 Injection in Patient With Advanced Solid Tumors

Phase 1
Not yet recruiting
Conditions
Interventions
First Posted Date
2022-08-19
Last Posted Date
2022-08-19
Lead Sponsor
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Target Recruit Count
128
Registration Number
NCT05508659

Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy

First Posted Date
2021-10-04
Last Posted Date
2024-12-12
Lead Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Target Recruit Count
14
Registration Number
NCT05065866
Locations
🇺🇸

Moffitt Cancer Center, Tampa, Florida, United States

Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC

First Posted Date
2021-09-27
Last Posted Date
2023-12-07
Lead Sponsor
Glenn J. Hanna
Target Recruit Count
26
Registration Number
NCT05057247
Locations
🇺🇸

Dana Farber Cancer Institute, Boston, Massachusetts, United States

Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy

First Posted Date
2021-09-14
Last Posted Date
2024-11-05
Lead Sponsor
Washington University School of Medicine
Target Recruit Count
43
Registration Number
NCT05044039
Locations
🇺🇸

Washington University School of Medicine, Saint Louis, Missouri, United States

A Study of Ruxolitinib and Duvelisib in People With Lymphoma

First Posted Date
2021-08-18
Last Posted Date
2024-08-23
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
49
Registration Number
NCT05010005
Locations
🇺🇸

Dana Farber Cancer Institute, Boston, Massachusetts, United States

🇺🇸

University of Miami (Data Collection Only), Miami, Florida, United States

🇺🇸

Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States

and more 6 locations

Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study

First Posted Date
2021-05-18
Last Posted Date
2023-10-13
Lead Sponsor
Emory University
Target Recruit Count
20
Registration Number
NCT04890236
Locations
🇺🇸

Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States

🇺🇸

University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States

Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma

First Posted Date
2021-03-17
Last Posted Date
2024-08-02
Lead Sponsor
Alliance for Clinical Trials in Oncology
Target Recruit Count
170
Registration Number
NCT04803201
Locations
🇺🇸

Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

🇺🇸

Memorial Hospital East, Shiloh, Illinois, United States

🇺🇸

University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania, United States

and more 74 locations
© Copyright 2024. All Rights Reserved by MedPath